/C O R R E C T I O N -- Heng Ren Partners/
In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issuedNov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at th...
Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share
BOSTON, April 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter onApril 8, 2025, to Sinovac's Board calling on the Board to disclose the record and payment dates of the special cash dividend announced onApril 1, 2025. More than a week af...
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liqui...
Sinovac Reports Unaudited First Half of 2018 Financial Results
BEIJING, Nov. 8, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, announced today its unaudited financial results for the six months endedJune 30, 2018. Financial highlights * Sales revenue for the...
U.S. District Court in Massachusetts Denies 1Globe's Motion for Preliminary Injunction to Enjoin Sinovac's Issuance of Shares
BEIJING, Oct. 17, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, today announced that the United States District Court of the District ofMassachusetts denied 1Globe Capital LLC's ("1Globe") August 20...
DOJ Closes Investigation of Sinovac
BEIJING, Sept. 17, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, today announced that the U.S. Department of Justice ("DOJ") has closed its investigation, with no charges, into possible violations of...
SEC Concludes Investigation of Sinovac
BEIJING, Aug. 20, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, today announced that the U.S. Securities and Exchange Commission ("SEC") has concluded its investigation into possible violations of th...
Sinovac Raises $86.73 Million Through Private Placement Transaction
* Vivo Capital and Advantech Capital Each Hold an Approximately 8.3% Stake in Sinovac After the Private Placement Transaction * Proceeds Will Be Used to Fund Improvement and Construction of Facilities for R&D Relating to Quality Control and Production of New Vaccines Projects * Sinovac's Boa...
Sinovac Files Motion for Summary Judgment on Rights Agreement in Delaware Chancery Court
* The summary judgment motion asks the Delaware Court to ascertain whether a trigger event under its Rights Agreement has occurred * The Company recently obtained information demonstrating that the Sinobioway Consortium and the Dissident Shareholdersreached an agreement in advance of the Annu...
Sinovac Biotech Relaunches Company Website
BEIJING, June 11, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA
Sinovac Files 2017 Annual Report on Form 20-F and Reports Unaudited Second Half, Audited Full Year 2017 Financial Results
BEIJING, May 11, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, announced today that it has filed its annual report for the year ended December 31 on Form 20-F (the "2017 Annual Report") with the U.S....
Sinovac Forced to Temporarily Suspend Hepatitis A Vaccine Production Line Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
Actions of Aihua Pan continue to harm the Company's shareholders and customers BEIJING, May 8, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products inChina, today announced it has been forced to suspend production...
Sinovac Forced to Temporarily Suspend Flu Vaccine Production Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
BEIJING, May 1, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products inChina, today announced it has been forced to temporarily suspend its flu vaccine production and destroy the flu vaccines it is currently produc...
Sinovac Forced to Plan to Destroy Bacterial Seeds intended for Pneumo Vaccine Production and Postpone Site Inspection
BEIJING, April 30, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, today announced it has been forced to destroy the bacterial seeds intended for use in the production of its 23-valent pneumococcal pol...
Sinovac Temporarily Blocks Access to Its Websites
BEIJING, April 30, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, today announced that Aihua Pan, the Chairman of the Board of the Company's controlled Chinese subsidiary, Sinovac Biotech Co., Ltd. ("...
Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing
BEIJING, April 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products inChina, today announced that it will delay the filing of its annual report on Form 20-F forthe year 2017 (the "2017 Annual Report"). The delay...
Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction
BEIJING, April 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that on April 26, 2018, it entered into Amendment No. 2 to the Amalgamation Agreement (the "Amendment") to further ame...
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
BEIJING, April 19, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products inChina, today announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine ("sIPV") developed by Sinovac Bi...
Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd.
- Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsidiary – - Reaffirms Commitment to Take All Appropriate Actions to Protect Company and Shareholder Interests – BEIJING, April 18, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: S...
Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction
BEIJING, March 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that on March 26, 2018, it entered into Amendment No. 1 to the Amalgamation Agreement (the "Amendment") to amend the A...
